Prime Medicine (PRME) Assets (2021 - 2026)
Prime Medicine's (PRME) quarterly Assets came in at $294.7 million in Q1 2026, down 10.19% YoY from $328.2 million in Q1 2025, and down 14.01% on a QoQ basis from $342.7 million in Q4 2025.
Prime Medicine (PRME) Assets (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Assets data on file, last reported at $294.7 million in Q1 2026.
- Quarterly Assets fell 10.19% year-over-year to $294.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $294.7 million (down 10.19% YoY) and the FY2025 annual result came in at $342.7 million, up 15.2% from the prior year.
- Assets declined to $294.7 million in Q1 2026, from $342.7 million in the prior quarter.
- In the past five years, Assets ranged from a high of $385.0 million in Q3 2025 to a low of $193.9 million in Q4 2023.
- A 5-year average of $295.8 million and a median of $297.5 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets tumbled 46.2% — and 2024, when it jumped 53.47%.
- Tracing PRME's Assets over 5 years: stood at $360.3 million in 2022, then sank by 46.2% to $193.9 million in 2023, then surged by 53.47% to $297.5 million in 2024, then gained by 15.2% to $342.7 million in 2025, then slipped by 14.01% to $294.7 million in 2026.
- The last three Assets figures came in at $294.7 million (Q1 2026), $342.7 million (Q4 2025), and $385.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 249.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 249.04 Mn |
| Mar 31, 2026 | 294.73 Mn |
| Dec 31, 2025 | 342.73 Mn |
| Sep 30, 2025 | 385.01 Mn |
| Jun 30, 2025 | 279.01 Mn |
| Mar 31, 2025 | 328.16 Mn |
| Dec 31, 2024 | 297.51 Mn |
| Sep 30, 2024 | 332.78 Mn |
| Jun 30, 2024 | 259.71 Mn |
| Mar 31, 2024 | 311.38 Mn |
| Dec 31, 2023 | 193.85 Mn |
| Sep 30, 2023 | 239.15 Mn |
| Jun 30, 2023 | 280.87 Mn |
| Mar 31, 2023 | 316.95 Mn |
| Dec 31, 2022 | 360.31 Mn |
| Sep 30, 2022 | 215.27 Mn |
| Dec 31, 2021 | 301.86 Mn |